Skip to main content
SpringerLink
Log in

Oral Tegafur/Uracil: profile report

  • New Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wellington K, Goa K. Oral Tegafur/Uracil: a viewpoint. Drugs Aging 2001; 18(12) 938–948

    Article  Google Scholar 

  2. Kato T. Tegafur/Uracil: a viewpoint. Drugs Aging 2001; 18(12) 949–950

    Article  Google Scholar 

  3. Feliu J. Tegafur/Uracil: a viewpoint. Drugs Aging 2001; 18(12) 949–950

    Article  Google Scholar 

  4. Pazdur R, Hoff PM, Medgyesy D, et al. The oral fluorouracil prodrugs. Oncology (Huntington) 1998; 12(10): 48–51

    CAS  Google Scholar 

  5. Pazdur R, Douillard J-Y, Skillings JR, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer [abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18

    Google Scholar 

  6. Carmichael J, Popiela D, Radstone S, et al. Randomized comparative study of ORZEL® (oral uracil/tegafur (UFT™) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer [abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18

    Google Scholar 

  7. Díáz-Rubio E, Sastre J, Abad A, et al. UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology (Huntington) 1999; 13 (Suppl. 3): 35–40

    Google Scholar 

  8. Feliu J, González-Barón M, Espinosa E, et al. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 1997; 79: 1884–9

    Article  PubMed  CAS  Google Scholar 

  9. Ferrari VD, Barni S, Mandalà M, et al. Tegafur (T) plus folinic acid (FA) as first line treatment of advanced colorectal cancer (ACC) in patients (pts) aged over 70 years. GISCAD (Ialian [sic] Group for the Study of Digestive Tract Cancer). Ann Oncol 2000; 11 (Suppl. 4): abstract no. 235P

  10. Hoff PM, Janjan N, Saad ED, et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 2000; 18: 3529–34

    PubMed  CAS  Google Scholar 

  11. Bristol-Myers Squibb Company — Oncology Division Europe. UFT® — tegafur-uracil capsules: product overview [media release]. 2001

  12. Bristol-Myers Squibb Pharmaceuticals Ltd. Uftoral capsules [online]. Available from URL: http://emc.vhn.net [Accessed 2001 Nov 27]

  13. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22(4): 333–8

    Article  PubMed  CAS  Google Scholar 

  14. Ikeda E, Kodaira S, Teramoto T, et al. Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer-phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration-Study Group of UFTM Therapy for Advanced Colorectal Cancer [in Japanese]. Gan To Kagaku Ryoho 1996; 23: 1291–8

    PubMed  CAS  Google Scholar 

  15. Kusunoki M, Yanagi H, Noda M, et al. The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. Oncol Rep 1999; 6: 547–52

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oral Tegafur/Uracil: profile report. Drugs Ther. Perspect 18, 5–6 (2002). https://doi.org/10.2165/00042310-200218070-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218070-00002

Keywords

Search

Navigation